A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancer

作者：Shigematsu Hideo^*; Kadoya Takayuki; Kobayashi Yoshie; Kajitani Keiko; Sasada Tatsunari; Emi Akiko; Masumoto Norio; Haruta Rumi; Kataoka Tsuyoshi; Oda Miyo; Arihiro Kouji; Okada Morihito

来源：World Journal of Surgical Oncology, 2011, 9: 146.

DOI：10.1186/1477-7819-9-146

• discordance
• HER-2
• trastuzumab
• recurrent breast cancer

We report a case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy 6 years after primary treatment of triple-negative breast cancer. The primary tumor was negative for HER-2 as determined by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) (1+, and ratio, 1.1), but examination of the recurrent lymph node metastasis showed positivity for HER-2 by FISH (ratio, 5.2). No lesions were detected in either her left breast or in other organs, and the patient was diagnosed as having HER-2-positive recurrent disease. Combination chemotherapy using weekly paclitaxel and trastuzumab was initiated, and a clinically complete response was achieved. This report suggests the benefit of routine evaluation of HER-2 status in recurrent breast cancer with the introduction of HER-2-targeting agents.

• 出版日期2011-11-7